Effect of ginger versus placebo on urinary cystatin C in patients with diabetes mellitus

Effect of ginger versus placebo on urinary cystatin C in patients with diabetes mellitus: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N504

Enrollment

Registered

2024-03-13

Start date

2024-04-08

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus. Type 1 diabetes mellitus

Interventions

Intervention 1: Intervention group: Oral drops containing ginger extract including monoterpenoids and sesquiterpenoids, beta-sesquoi-flandrene and beta-bisabolone (manufactured by Zardband Pharmaceuti

Eligibility

Sex/Gender

All

Age

6 Years to 17 Years

Inclusion criteria

Inclusion criteria: Age 6 to 17 years Type 1 diabetes for at least 5 years

Exclusion criteria

Exclusion criteria: Bleeding disorders Urinary tract infection Acute febrile infection Liver or kidney disease

Design outcomes

Primary

Measure	Time frame
Urinary cystatin C level. Timepoint: Before the intervention and 2 months later. Method of measurement: By urinalysis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hosein Emad Momtaz

Hamedan University of Medical Sciences

hemmtz@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026